Matrix Metalloproteinases-3, -9, and Prolidase: A Promising Therapeutic Strategy Targeting Breast Cancer
MMP-3, MMP-9 & Prolidase in Breast Cancer
DOI:
https://doi.org/10.29409/k053zy34Keywords:
Breast Cancer, Metalloproteinase, Prolidase, Angiogenesis and Target therapyAbstract
Matrix metalloproteinases (MMPs) are tightly regulated enzymes that play a significant role in tissue remodeling. They are produced by normal and tumor cells and participate in extracellular matrix remodeling and degradation of basement membrane barriers. During tumor progression, cancer cells invade surrounding tissues, accompanied by numerous alterations, leading to microenvironmental stress and breakdown of the extracellular matrix, including loss of basement membrane integrity caused by dysfunction of metalloproteinase activity. This review summarizes the significant roles of MMP-3, -9, and prolidase in different stages of breast cancer progression to offer a comprehensive understanding of the main contributions of these enzymes in breast tumors. Studies have indicated that elevated expression and enzymatic activity correlate with tumor progression through the modulation of transcription factor activity and metastasis mechanisms. MMP-3 is involved in angiogenesis; inhibition of MMP-3 activity is considered a potential therapeutic strategy. In contrast, MMP-9 plays a restrictive role in angiogenesis. Numerous studies have shown that targeting tissue inhibitors of MMPs or silencing these enzymes represents a promising therapeutic strategy to suppress tumor growth and enhance apoptosis. MMP-3, MMP-9, and prolidase should not be considered independent regulators of extracellular matrix remodeling; they function through interconnected mechanisms that govern the dynamic remodeling of cancer progression. Few studies have investigated prolidase activity and its role in pathological processes, and its precise association with MMP-3 and MMP-9 in breast cancer remains poorly understood. Currently, no studies have directly discussed the relationship between MMP-3 and prolidase; however, few mechanistic studies have indicated that prolidase acts as an upstream regulator of MMP-3 and MMP-9 in breast cancer. Further experimental investigations are needed to clarify the interplay of these enzymes in extracellular matrix remodeling within the breast tumor microenvironment to support the development of a prospective therapeutic approach.
References
1. Xiong X, Zheng LW, Ding Y. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19; 10(1):49. https://doi.org/10.1038/s41392-024-02108-4
2. Ashja Ardalan A, Khalili-Tanha G, Shoari A. Shaping the landscape of lung cancer: the role and therapeutic potential of matrix metalloproteinases. Int J Transl Med. 2024 Nov 22; 4(4):661-679. https://doi.org/10.3390/ijtm4040046
3. Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int J Mol Sci. 2021 Dec 23; 23(1):146.. https://doi.org/10.3390/ijms23010146
4. Castro-Castro A, Marchesin V, Monteiro P, Lodillinsky C, Rossé C, Chavrier P. Cellular and molecular mechanisms of MT1-MMP-dependent cancer cell invasion. Annu Rev Cell Dev Biol. 2016 Oct 6; 32(1):555-576. https://doi.org/10.1146/annurev-cellbio-111315-125227
5. Mustafa S, Koran S, AlOmair L. Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review. Front Mol Biosci. 2022 Sep 29; 9:896099. https://doi.org/10.3389/fmolb.2022.896099
6. Cerofolini L, Fragai M, Luchinat C. Mechanism and inhibition of matrix metalloproteinases. Curr Med Chem. 2019 May 1; 26(15):2609-2633.https://doi.org/10.2174/0929867325666180326163523
7. Kwon MJ. Matrix metalloproteinases as therapeutic targets in breast cancer. Front Oncol. 2023 Jan 19; 12:1108695. https://doi.org/10.3389/fonc.2022.1108695
8. Kudelski J, Młynarczyk G, Gudowska-Sawczuk M, Mroczko B, Darewicz B, Bruczko-Goralewska M, et, al. Enhanced expression but decreased specific activity of matrix metalloproteinase 10 (MMP-10) in comparison with matrix metalloproteinase 3 (MMP-3) in human urinary bladder carcinoma. J Clin Med. 2021 Aug 19; 10(16):3683. https://doi.org/10.3390/jcm10163683
9. Kim IS, Yang WS, Kim CH. Physiological properties, functions, and trends in the matrix metalloproteinase inhibitors in inflammation-mediated human diseases. Curr Med Chem. 2023 Jun 1; 30(18):2075-2112. https://doi.org/10.2174/0929867329666220510102212
10. Piskór BM, Przylipiak A, Dąbrowska E, Niczyporuk M, Ławicki S. Matrilysins and stromelysins in pathogenesis and diagnostics of cancers. Cancer Manag Res. 2020 Oct 30; 12:10949-10964. https://doi.org/10.2147/CMAR.S268430
11. Młynarczyk G, Gudowska-Sawczuk M, Mroczko B, Bruczko-Goralewska M, Romanowicz L, Tokarzewicz A. Higher content but no specific activity in gelatinase B (MMP-9) compared with gelatinase A (MMP-2) in human renal carcinoma. Cancers (Basel). 2023 Nov 20; 15(22):5475. https://doi.org/10.3390/cancers15225475
12. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000 Dec 1; 10(6):415-433. https://doi.org/10.1006/scbi.2000.0377
13. Ren W, Liu Y, Wan S, Fei C, Wang W, Chen Y, et al. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 2014 May 7; 9(5):e96816. https://doi.org/10.1371/journal.pone.0096816
14. Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S,et al . Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020 Jul; 182(2):267-282. https://doi.org/10.1007/s10549-020-05670-x
15. Eni-Aganga I, Lanaghan ZM, Balasubramaniam M, Dash C, Pandhare J. PROLIDASE: A review from discovery to its role in health and disease. Front Mol Biosci. 2021 Aug 31; 8:723003. https://doi.org/10.3389/fmolb.2021.723003
16. Wilk P, Uehlein M, Kalms J, Dobbek H, Mueller U, Weiss MS. Substrate specificity and reaction mechanism of human prolidase. FEBS J. 2017 Sep; 284(17):2870-2885. https://doi.org/10.1111/febs.14113
17. Prokop I, Konończuk J, Surażyński A, Pałka J. Cross-talk between integrin receptor and insulin-like growth factor receptor in regulation of collagen biosynthesis in cultured fibroblasts. Adv Med Sci. 2013 Dec 1; 58(2):292-297. https://doi.org/10.2478/ams-2013-0016
18. Mahmood NA, Abdulghany ZS, Al-Sudani IM. The expression levels of matrix metalloproteinases inhibitors TIMP1, TIMP2 and matrix metalloproteinases MMP2, MMP9 in Iraqi patients diagnosed with colon cancer. Govaresh. 2019 Sep 23; 24(3):172-178.
19. Mirastschijski U, Lupše B, Maedler K, Sarma B, Radtke A, Belge G, Dorsch M, Wedekind D, McCawley LJ, Boehm G, Zier U. Matrix metalloproteinase-3 is key effector of TNF-α-induced collagen degradation in skin. Int J Mol Sci. 2019 Oct 22; 20(20):5234. https://doi.org/10.3390/ijms20205234
20. Wan J, Zhang G, Li X, Qiu X, Ouyang J, Dai J, et al. Matrix metalloproteinase 3: a promoting and destabilizing factor in the pathogenesis of disease and cell differentiation. Front Physiol. 2021 Jul 2; 12:663978. https://doi.org/10.3389/fphys.2021.663978
21. Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr Res. 2021 May; 89(7):1619-1626. https://doi.org/10.1038/s41390-020-01188-4
22. Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017 Jan 1; 147:1-73. https://doi.org/10.1016/bs.pmbts.2017.02.005
23. Misiura M, Miltyk W. Current understanding of the emerging role of prolidase in cellular metabolism. Int J Mol Sci. 2020 Aug 17; 21(16):5906. https://doi.org/10.3390/ijms21165906
24. Surazyński A, Pałka J, Wołczyński S. Acetylsalicylic acid dependent inhibition of collagen biosynthesis and beta1-integrin signaling in cultured fibroblasts. Med Sci Monit. 2004 Jan 10; 10(1):BR175-BR179.
25. Coates-Park S, Rich JA, Stetler-Stevenson WG, Peeney D. The TIMP protein family: diverse roles in pathophysiology. Am J Physiol Cell Physiol. 2024 Mar 1; 326(3):C917-C934. https://doi.org/10.1152/ajpcell.00409.2023
26. Raeeszadeh-Sarmazdeh M, Greene KA, Sankaran B, Downey GP, et al. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition. J Biol Chem. 2019 Jun 14;294(24):9476-9488. https://doi.org/10.1074/jbc.RA119.008663
27. Du X, Wang S, Lu J, Cao Y, Song N, Yang T, et al. Correlation between MMP1–PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol. 2011 Sep 1;41(9):1086-1093. https://doi.org/10.1093/jjco/hyr095
28. Javadian M, Gharibi T, Shekari N. The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasis. J Cell Physiol. 2019 May;234(5):5399-5412. https://doi.org/10.1002/jcp.27439
29. Xia H, Yu W, Liu M. An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer. Oncol Lett. 2019 Sep 1;18(3):2985-2994. https://doi.org/10.3892/ol.2019.10601
30. Chu C, Liu X, Bai X, Zhao T, Wang M, Xu R, et al. MiR-519d suppresses breast cancer tumorigenesis and metastasis via targeting MMP3. Int J Biol Sci. 2018 Feb 9;14(2):228-240. https://doi.org/10.7150/ijbs.22030
31. Liu H, Cao YD, Ye WX, Sun YY. Effect of microRNA-206 on cytoskeleton remodelling by downregulating Cdc42 in MDA-MB-231 cells. Tumori. 2010 Sep;96(5):751-755. https://doi.org/10.1177/030089161009600512
32. Song B, Wang C, Liu J,Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 2010;29:29. https://doi.org/10.1186/1756-9966-29-29
33. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. Small molecule inhibitors of microRNA miR-21 function. Angew Chem Int Ed Engl. 2008;47(39):7482-7484. https://doi.org/10.1002/anie.200801555
34. Wang Y, Dong L, Wan F, Chen F, Liu D, Chen D, et al. MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH. Cell Death Dis. 2021 Sep 22;12(10):861. https://doi.org/10.1038/s41419-021-04161-z
35. Shoari A, Coban MA, Hockla A. Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. J Biol Chem. 2025 May 21;300:110258.
36. Argote Camacho AX, Gonzalez Ramirez AR, Perez Alonso AJ. Metalloproteinases 1 and 3 as potential biomarkers in breast cancer development. Int J Mol Sci. 2021 Aug 20;22(16):9012. https://doi.org/10.3390/ijms22169012
37. Kim GE, Lee JS, Choi YD. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer. 2014 Dec 16;14(1):959. https://doi.org/10.1186/1471-2407-14-959
38. Ławicki P, Malinowski P, Motyka J. Plasma levels of metalloproteinase 3 (MMP-3) and metalloproteinase 7 (MMP-7) as new candidates for tumor biomarkers in diagnostic of breast cancer patients. J Clin Med. 2023 Mar 30;12(7):2618. https://doi.org/10.3390/jcm12072618
39. Suhaimi SA, Chan SC, Rosli R. Matrix metallopeptidase 3 polymorphisms: emerging genetic markers in human breast cancer metastasis. J Breast Cancer. 2020 Feb;23(1):1-9. https://doi.org/10.4048/jbc.2020.23.e5
40. Benson CS, Babu SD, Radhakrishna S. Expression of matrix metalloproteinases in human breast cancer tissues. Dis Markers. 2013 May;34(6):395-405. https://doi.org/10.1155/2013/913804
41. Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC. Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer. 2015 Nov;6(11-12):480-489. https://doi.org/10.18632/genesandcancer.90
42. Balkhi S, Mashayekhi F, Salehzadeh A. Matrix metalloproteinase (MMP)-1 and MMP-3 gene variations affect MMP-1 and -3 serum concentration and associate with breast cancer. Mol Biol Rep. 2020 Jun;47(12):9637-9644. https://doi.org/10.1007/s11033-020-05989-4
43. Padala C, Tupurani MA, Puranam K,Gantala S, Shyamala N, Kondapalli MS, Gundapaneni KK, , et al. Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 2017 Sep 29;12(9):e0184448. https://doi.org/10.1371/journal.pone.0184448
44. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013 May 16;8(5):e63165. https://doi.org/10.1371/journal.pone.0063165
45. Olivares-Urbano MA, Griñán-Lisón C, Zurita M,Del Moral R, Ríos‐Arrabal S, Artacho‐Cordón F, , et al. Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: a pilot study. J Cell Mol Med. 2020 Jan;24(1):139-148. https://doi.org/10.1111/jcmm.14795
46. Argote Camacho AX, Gonzalez Ramirez AR, Perez Alonso AJ,Rejon Garcia JD, Olivares Urbano MA, et al. Metalloproteinases 1 and 3 as potential biomarkers in breast cancer development. Int J Mol Sci. 2021 Aug 20;22(16):9012. https://doi.org/10.3390/ijms22169012
47. Taha EA, Sogawa C, Okusha Y, et al. Knockout of MMP3 weakens solid tumor organoids and cancer extracellular vesicles. Cancers (Basel). 2020 May 16;12(5):1260. https://doi.org/10.3390/cancers12051260
48. Martins LM, Dourado CS, Campos-Verdes LM, Sampaio FA, Revoredo CM, Costa-Silva DR, et al. Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma: a randomized, double-blind study. Oncotarget. 2019 Dec 3;10(64):6879-6889. https://doi.org/10.18632/oncotarget.27390
49. Bakir WA, Ashoor ZA, Ismil NH, Majeed AM. Prevalence of matrix metalloproteinase-9 in breast cancer as a marker of prognosis. Iraqi J Biotechnol. 2014 May;13(2):266-272.
50. Mahmood NA, Fakhoury RM, Yaseen NY. Matrix metalloproteinases MMP2 and MMP9 expression in stages II-III breast cancer in Iraqi women. J Med Biol Sci Res. 2015 May;1(3):30-37.
51. Kalavska K, Cierna Z, Karaba M. Prognostic role of matrix metalloproteinase 9 in early breast cancer. Oncol Lett. 2021 Feb;21(2):78. https://doi.org/10.3892/ol.2020.12329
52. Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S,et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res Treat. 2020 Jul;182(2):267-282. https://doi.org/10.1007/s10549-020-05670-x
53. Bayhan Z, Zeren S, Kocak C. Prolidase activity and oxidative stress in patients with breast carcinoma: a prospective randomized case-controlled study. Ann Ital Chir. 2016 Sep 1;87(6):517-524.
54. Abusoglu S, Eryavuz D, Bal C. Assessment of serum ischemia-modified albumin, prolidase and thiol-disulphide levels in subjects with breast cancer. Rev Rom Med Lab. 2019 Feb 1;27(1):25-33. https://doi.org/10.2478/rrlm-2019-0004
55. Hussien SA, Rasool KH, Zaki NH. Evaluation of the effect of purified prolidase from Escherichia coli on some immunological aspects. Rev Res Med Microbiol. 2025 Jul 1;36(3):121-133.
56. Zareba I, Palka J. Prolidase-proline dehydrogenase/proline oxidase-collagen biosynthesis axis as a potential interface of apoptosis/autophagy. Biofactors. 2016 Jul 8;42(4):341-348. https://doi.org/10.1002/biof.1281
57. Hong OY, Jang HY, Park KH,Jeong YJ, Kim JS, Chae HS. Triptolide inhibits matrix metalloproteinase-9 expression and invasion of breast cancer cells through the inhibition of NF-κB and AP-1 signaling pathways. Oncol Lett. 2021 Jul;22(1):562. https://doi.org/10.3892/ol.2021.12779
58. Mi C, Shi H, Ma J, Han LZ, Lee JJ, Jin X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep. 2014 Dec;32(6):2527-2532. https://doi.org/10.3892/or.2014.3496
59. Guo Y, Zhang Y, Yang X, Lu P, Yan X, Xiao F, et al. Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cell proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther. 2016 Feb 1;17(2):169-180. https://doi.org/10.1080/15384047.2015.1108498
60. Lewoniewska S, Oscilowska I, Forlino A, Palka J. Understanding the role of estrogen receptor status in PRODH/POX-dependent apoptosis/survival in breast cancer cells. Biology (Basel). 2021 Dec 10;10(12):1314. https://doi.org/10.3390/biology10121314
61. Reggiani F, Labanca V, Mancuso P, Rabascio C, Talarico G, Orecchioni S, ,et al. Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res. 2017 Sep 15;77(18):5169-5182. https://doi.org/10.1158/0008-5472.CAN-17-0914
62. Chen Y, Wang W, Liu F, Tang L, Tang R, Li W. Apoptotic effect of matrix metalloproteinase 9 in the development of diabetic retinopathy. Int J Clin Exp Pathol. 2015;8:10452-10459.
63. Elmetwalli A, Abdel-Monem MO, El-Far AH,Ghaith GS, Albalawi NA, Hassan J, et al. Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2-dependent AMPK activation for hepatic cancer treatment. Med Oncol. 2024 Apr 4;41(5):106. https://doi.org/10.1007/s12032-024-02341-2
64. Baszanowska W, Niziol M, Oscilowska I, Czyrko-Horczak J, Miltyk W, Palka J. Recombinant human prolidase (rhPEPD) induces wound healing in experimental model of inflammation through activation of EGFR signalling in fibroblasts. Molecules. 2023 Jan 14;28(2):851. https://doi.org/10.3390/molecules28020851
65. Jabłońska-Trypuć A, Matejczyk M, Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 2016 Nov 1;31(Suppl 1):177-183. https://doi.org/10.3109/14756366.2016.1161620
Additional Files
Received
Revised
Accepted
Published
Data Availability Statement
The data is available for readers.
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Cancer and Medical Genetics
This work is licensed under a Creative Commons Attribution 4.0 International License.
